RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase trial is testing the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer whose cancer worsened after previous treatment. About 138 participants will receive both drugs to see if the combination…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:08 UTC
-
Could adding durvalumab early beat lung cancer?
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:08 UTC
-
New combo therapy aims to boost lung cancer survival
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:07 UTC
-
New radiation approach aims to boost tumor kill while sparing healthy tissue
Disease control OngoingThis study tests a new way to give radiation to people with stage II to III non-small cell lung cancer. The goal is to deliver a higher dose directly to the tumor while keeping the dose to nearby healthy organs at standard levels. About 146 participants will receive either photon…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:07 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. The main goal is to find the safest dose and check for side effects. About 36 particip…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:07 UTC
-
Experimental combo aims to boost Radiation's punch against returning lung tumors
Disease control OngoingThis early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:05 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. The trial combines two drugs: brigatinib (which blocks cancer growth signals) and bevacizumab (whi…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
New drug duo targets hard-to-treat lung cancer
Disease control OngoingThis early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goals are to find the safest dose and see if the combination can shrink tumors or slow the…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
Engineered cord blood cells take on tough lung cancers
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets tough lung cancers in Biomarker-Guided trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and pembrolizumab, in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see how well this treatment works based on specific genetic markers in each patient's tumor. About 37 particip…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug cocktail aims to outperform chemo in tough lung cancer cases
Disease control OngoingThis phase 3 trial compares a combination of two drugs (ramucirumab and pembrolizumab) against standard chemotherapy for people with stage IV or recurrent non-small cell lung cancer whose disease worsened after initial immunotherapy. About 838 participants will be randomly assign…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Combining targeted drug with local treatments may extend control of EGFR lung cancer
Disease control OngoingThis study looks at whether adding surgery or radiation to the targeted therapy osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 173 participants with stage IIIB or IV lung cancer will be randoml…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests two drugs, erlotinib and cabozantinib, given alone or together in people with advanced non-small cell lung cancer that has not responded to earlier treatments. The goal is to see if the combination works better than either drug alone at slowing cancer growth. Abo…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study tests whether combining two drugs, trametinib and docetaxel, can shrink tumors in people with a specific genetic form of advanced lung cancer (KRAS mutation). The trial includes 60 patients whose cancer has worsened after one or two prior treatments. The main goal is t…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Vitamin a derivative joins immunotherapy in fight against advanced lung cancer
Disease control OngoingThis early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo attack on hard-to-treat lung cancer shows early promise
Disease control OngoingThis early trial tested a two-pronged approach for people with advanced ALK-positive non-small cell lung cancer. Participants first received a targeted drug (brigatinib), then local treatments like surgery or radiation to any remaining tumors. The goal was to see if this combinat…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New cocktail targets tough lung cancer in early trial
Disease control OngoingThis early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose and check safety of adding ensartinib to standard chemotherapy and bevacizumab. About 12 participants with stage IIIC or IV dise…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Blood test may tame Chemo's nerve damage
Knowledge-focused TerminatedThis study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated May 17, 2026 01:08 UTC